RNA sequencing to identify fusion transcripts in late-stage relapse patients with estrogen receptor positive breast cancer
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA782878 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR17015817.fastq.gz | Fastqsanger.gz | |||
| SRR17015817_1.fastq.gz | Fastqsanger.gz | |||
| SRR17015817_2.fastq.gz | Fastqsanger.gz | |||
| SRR17015818.fastq.gz | Fastqsanger.gz | |||
| SRR17015818_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 72 |
Similar Datasets
Project description:RNA sequencing (RNA-seq) detects estrogen receptor alpha gene (ESR1) fusion transcripts in estrogen receptor positive (ER+) breast cancer but their role in disease pathogenesis remains unclear. We performed sequencing on RNA extracted from metastatic biopsy samples from patients with ER+ breast cancer to assess the presence of fusion transcripts.
2021-11-23 | GSE189389 | GEO
Project description:RNA sequencing (RNA-seq) detects estrogen receptor alpha gene (ESR1) fusion transcripts in estrogen receptor positive (ER+) breast cancer but their role in disease pathogenesis remains unclear. Herein we examined multiple in-frame and out-of-frame ESR1 fusions and found that two, both identified in advanced endocrine treatment resistant disease, encoded stable and functional in-frame fusion proteins. In both examples, ESR1-e6>YAP1 and ESR1-e6>PCDH11X, the N-terminal, DNA binding and dimerization motifs encoded by exons 2-6 were fused to C terminal sequences from the partner gene. Functional properties included estrogen-independent growth, constitutive expression of ER target genes, anti-estrogen resistance, induction of cellular motility in vitro and the development of lung metastasis in vivo. Chromatin immunoprecipitation and RNA sequencing experiments showed both fusions uniquely activated a metastasis-associated transcriptional program. ESR1-e6>YAP1 and ESR1-e6>PCDH11X-induced growth remained sensitive to a CDK4/6 inhibitor, palbociclib, and a patient-derived xenograft (PDX) naturally expressing the ESR1-e6>YAP1 fusion was also responsive. Transcriptionally active ESR1 fusions therefore trigger both endocrine therapy resistance and metastatic progression explaining the association with fatal disease progression, although CDK4/6 inhibitor treatment is predicted to be effective.
2018-07-11 | GSE116170 | GEO
Project description:Identification of novel fusion transcripts in neuroblastoma
| PRJNA605944 | ENA
Project description:Transcriptional properties of estrogen receptor fusion genes.
| PRJNA477539 | ENA
Project description:Searching for the fusion transcripts created during proteotoxic stress
| PRJEB73803 | ENA
Project description:Acute myeloid leukemia (AML) is characterized by serious aggressivity of high relapse risk and various molecular aberrations. Rearrangements involving NUP98 with multiple fusing partner genes in myeloid malignancies indicate dismal survival outcomes. Mechanisms contributing to subsequent aggressive progression and severe relapse risk of NUP98-rearranged AML remain undefined. Here we identified a novel oncogenic fusion RUNX1/ZNF423 in a relapse and refractory AML patient with NUP98/NSD1. And mice xenografted from the patient bearing both RUNX1/ZNF423 and NUP98/NSD1 display more severe engraftment levels than NUP98/NSD1 only. Mechanically, RUNX1/ZNF423 accompanied with NUP98/NSD1 recapitulated transcriptional signatures in hematopoietic differentiation blockage and altered amino acid metabolism pathway. Moreover, single-cell sequencing confirmed the coexistence of RUNX1/ZNF423 with NUP98/NSD1 in the same leukemic blast. Meanwhile, we also found that the coexistence of gene fusions in NUP98-rearranged AML was a significant phenomenon, which probably contributes to their worse clinical outcome. Finally, tailored intervention treatment based on ex vivo drug sensitivity testing is provided to this relapse and refractory AML patient and achieved favorable clinical response. Taken together, we not only identified a novel gene fusion RUNX1/ZNF423 with transforming potential detected in a NUP98-rearranged AML, but also achieved a deeper understanding into mechanisms contributing to disease relapse in AML.
2024-12-01 | GSE222098 | GEO
Project description:Acute myeloid leukemia (AML) is characterized by serious aggressivity of high relapse risk and various molecular aberrations. Rearrangements involving NUP98 with multiple fusing partner genes in myeloid malignancies indicate dismal survival outcomes. Mechanisms contributing to subsequent aggressive progression and severe relapse risk of NUP98-rearranged AML remain undefined. Here we identified a novel oncogenic fusion RUNX1/ZNF423 in a relapse and refractory AML patient with NUP98/NSD1. And mice xenografted from the patient bearing both RUNX1/ZNF423 and NUP98/NSD1 display more severe engraftment levels than NUP98/NSD1 only. Mechanically, RUNX1/ZNF423 accompanied with NUP98/NSD1 recapitulated transcriptional signatures in hematopoietic differentiation blockage and altered amino acid metabolism pathway. Moreover, single-cell sequencing confirmed the coexistence of RUNX1/ZNF423 with NUP98/NSD1 in the same leukemic blast. Meanwhile, we also found that the coexistence of gene fusions in NUP98-rearranged AML was a significant phenomenon, which probably contributes to their worse clinical outcome. Finally, tailored intervention treatment based on ex vivo drug sensitivity testing is provided to this relapse and refractory AML patient and achieved favorable clinical response. Taken together, we not only identified a novel gene fusion RUNX1/ZNF423 with transforming potential detected in a NUP98-rearranged AML, but also achieved a deeper understanding into mechanisms contributing to disease relapse in AML.
2024-12-01 | GSE221767 | GEO
Project description:To verify the hypothesis that proteotoxic stress induces the formation of fusion transcripts in non-cancerous and cancerous cells derived from breast epithelium, we exposed the cells to heat shock (HS, 1h at 43 degrees). We selected MCF10A non-tumorigenic breast epithelial cells (isolated from the mammary gland with fibrocystic disease) and MCF7 breast adenocarcinoma cells (estrogen receptor-positive, ER+). Global transcriptome analysis was performed in untreated cells and at 2h and 4h after HS. The TimeLapse-Seq method was used, which allows for obtaining information about newly produced RNA in relation to total RNA in one sequencing reaction [1]. To metabolically label the newly produced RNA, 4-thiouridine (4sU, a thymidine analog) was added to the medium for the duration of the experiment. To convert 4sU to cytidine analogs (providing U-to-C mutations that enable tagging of new transcripts when sequenced), samples were treated with 2,2,2-trifluoroethylamine (TFEA) and sodium periodate (NaIO4) as described in [1]. All libraries were sequenced on the Illumina NovaSeq6000 platform, in 2x150 mode, with a coverage of 200M reads/sample. Obtained data were subjected to the standard RNA-seq data analysis procedure, including the additional steps required for TimeLapse-Seq, described in [1]. Identification of gene fusions was performed using the Arriba tool [2]. [1] Schofield JA. et al. Nat Methods. 2018, 15:221-225. [2] Haas BJ. et al. Genome Biol. 2019, 20:213.
2024-12-01 | E-MTAB-13903 | biostudies-arrayexpress
Project description:Previous reports have described the use of microarrays to assess the molecular classification of human breast cancers and defined new subgroups based on gene expression that are relevant to patient management through their ability to predict metastatic relapse and survival relapse. However, different mechanisms may be associated with the development of early and late distant metastases. With the hypothesis that tumors may lead to early or distant metastases based on their intrinsic biological initial features. We aimed at defining molecular profiles for several subgroups of patients based on their outcome over time. Breast primary tumors were selected from retrospective series of patients with frozen material available. These series include patients of all ages, LN- and LN+; Estrogen or Progesteron-receptor positive, Her2-negative, no adjuvant treatment, with a follow-up of more than 10 years (y) for the control group or distant metastatic relapse as first event (DM) for the study group. Patients tumors were classified in 3 groups: no relapse at 10y (M0), DM before 5 y (M0-5), DM between 5 and 15 y (M5-15).Gene expression analysis of breast tumor samples was performed using custom-made Agilent 4x44K high-density microarrays and hybridized against the Mammaprint reference pool (MRP). MRP=MammaReference Pool (The reference sample consisted of pooled and amplified RNA of 105 primary breast tumors, see Glas AM, BMC Genomics, 2006). The design of this study consists to 20 hybridizations in dual color with Agilent Human Genome 4x44K (design 014850) of breast tumors with a MRP reference with an addition as controls of 2 dye swaps and two self-self of the MRP and HMG (Human normal mammary Gland , Clontech).
2013-08-01 | E-MTAB-949 | biostudies-arrayexpress
Project description:Gene expression profiles were analyzed from 60 children with first bone marrow relapse. Genes and pathways differentiating early vs. late relapse were identified. Signatures predicting early response to therapy were also identified. Keywords: ordered
2006-03-20 | GSE3911 | GEO